Clinical Trials · NCT07842172
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Washington University School of Medicine
- Enrollment
- 240
- Start date
- Nov 2026
- Locations
- 2 sites, United States
- Primary endpoint
- Progression-free survival (PFS)